On Tuesday, Bausch Health Companies Inc (NYSE: BHC) opened lower -2.35% from the last session, before settling in for the closing price of $9.35. Price fluctuations for BHC have ranged from $3.96 to $11.46 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1.03% over the past five years. Company’s average yearly earnings per share was noted 8.07% at the time writing. With a float of $325.07 million, this company’s outstanding shares have now reached $365.24 million.
Let’s look at the performance matrix of the company that is accounted for 20270 employees. In terms of profitability, gross margin is 98.96%, operating margin of 14.78%, and the pretax margin is -0.51%.
Bausch Health Companies Inc (BHC) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Bausch Health Companies Inc is 11.62%, while institutional ownership is 76.58%. The most recent insider transaction that took place on Sep 06 ’24, was worth 83,028. In this transaction EVP, General Counsel of this company sold 13,370 shares at a rate of $6.21, taking the stock ownership to the 435,198 shares. Before that another transaction happened on Sep 06 ’24, when Company’s Officer proposed sale 13,370 for $6.21, making the entire transaction worth $83,028.
Bausch Health Companies Inc (BHC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 8.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.37% during the next five years compared to 32.76% growth over the previous five years of trading.
Bausch Health Companies Inc (NYSE: BHC) Trading Performance Indicators
Check out the current performance indicators for Bausch Health Companies Inc (BHC). In the past quarter, the stock posted a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.49. Likewise, its price to free cash flow for the trailing twelve months is 4.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.48, a number that is poised to hit 1.12 in the next quarter and is forecasted to reach 4.28 in one year’s time.
Technical Analysis of Bausch Health Companies Inc (BHC)
Bausch Health Companies Inc (NYSE: BHC) saw its 5-day average volume 2.04 million, a negative change from its year-to-date volume of 2.92 million. As of the previous 9 days, the stock’s Stochastic %D was 63.61%. Additionally, its Average True Range was 0.33.
During the past 100 days, Bausch Health Companies Inc’s (BHC) raw stochastic average was set at 87.78%, which indicates a significant increase from 61.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.64% in the past 14 days, which was higher than the 61.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.03, while its 200-day Moving Average is $7.70. Nevertheless, the first resistance level for the watch stands at $9.33 in the near term. At $9.52, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.74. If the price goes on to break the first support level at $8.92, it is likely to go to the next support level at $8.70. Assuming the price breaks the second support level, the third support level stands at $8.51.
Bausch Health Companies Inc (NYSE: BHC) Key Stats
There are currently 367,803K shares outstanding in the company with a market cap of 4.67 billion. Presently, the company’s annual sales total 8,757 M according to its annual income of -592,000 K. Last quarter, the company’s sales amounted to 2,510 M and its income totaled -85,000 K.
